Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia
The Journal of Pharmacology and Experimental Therapeutics · 2025
DOI: 10.1124/jpet.124.002347 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von Sean M Smith und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Inc, Rahway, New Jersey. Electronic address: sean_smith2@merck.com. Hauptthemen laut MEDLINE: Schizophrenia, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Antipsychotic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co, Inc, Rahway, New Jersey. Electronic address: sean_smith2@merck.com.
- Merck & Co, Inc, Rahway, New Jersey.
Zitieren
APA
Smith, S. M., Toolan, D., Kandebo, M., Vardigan, J., Raheem, I., Layton, M. E., Kern, J. C., Cox, C., Gantert, L., Riffel, K., Hostetler, E., & Uslaner, J. M. (2025). Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.124.002347
Vancouver
Smith SM, Toolan D, Kandebo M, Vardigan J, Raheem I, Layton ME, et al. Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1124/jpet.124.002347
BibTeX
@article{Smith2025,
author = {Smith, Sean M and Toolan, Dawn and Kandebo, Monika and Vardigan, Joshua and Raheem, Izzat and Layton, Mark E and Kern, Jeffrey C and Cox, Christopher and Gantert, Liza and Riffel, Kerry and Hostetler, Eric and Uslaner, Jason M},
title = {Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
doi = {10.1124/jpet.124.002347}
}
EUVIMED